Boston Therapeutics has filed an abbreviated new drug application (or ANDA) with the Food and Drug Administration. The new drug appears in the form of chewable metformin, intended to help treat Type 2 diabetes.
The purpose of the medication is to aid in controlling blood sugar levels. It is to be used along with insulin or other medications for treating diabetes.
The CEO of Boston Therapeutics, David Platt, stated that this new medication complements Boston’s line of diabetes treatments. Boston also manufactures PZ-320, for management of blood glucose levels, and Ipoxyn, which treats limb ischemia.
According to chief technology officer Joan Sellers, Boston’s filing for this new ANDA represents a significant step in their diabetes treatment program.
